Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2003-06-06
2011-10-11
Schwadron, Ronald (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093710, C435S372000, C435S366000, C435S325000
Reexamination Certificate
active
08034332
ABSTRACT:
This invention relates to a natural killer cell line termed NK-92 and to NK-92 cell lines that have been modified by transfection with a vector to confer advantageous properties. The invention provides a modified NK-92 cell line that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. In a significant embodiment, the cytokine is interleukin 2. The invention additionally provides a modified NK-92 cell line that is transfected with a vector that expresses a thymidine kinase gene. The invention further provides a modified NK-92 cell line that is transfected with a vector that expresses a β2micrglobulin.
REFERENCES:
patent: 5272082 (1993-12-01), Santoli et al.
patent: 5772995 (1998-06-01), Fakhrai et al.
patent: 5981705 (1999-11-01), Kornbluth
patent: WO 98/48630 (1998-05-01), None
Klingemann et al., Blood, vol. 84, suppl 1, p. 498a, abstract 1978, 1994.
Foa et al., Natural Immunity, 13:65-75, 1994.
Tran et al., The J. of Immunol., 155:1000-1009, 1995.
Liu et al., Cellular Immunol., 156:24-35, 1994.
Ades, E.W., N. Peacocke, and H. Sabio. 1988. Lymphokine-activated killer cells lysis of human neuroblastoma cells: a model for purging tumor cells from bone marrow.Clin Immunol Immunopathol. 46:150-6.
Alderson, M.R., H.M. Sassenfeld, and M.B. Widmer. 1990. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.J Exp Med. 172:577-87.
Bluman, E.M., K.J. Bartynski, B.R. Avalos, and M.A. Caligiuri. 1996. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines.J Clin Invest. 97:2722-7.
Brooks, A.G., P.E. Posch, C.J. Scorzelli, F. Borrego, and J.E. Coligan. 1997. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor.J Exp Med. 185:795-800.
Burshtyn, D.N., A.M. Scharenberg, N. Wagtmann, S. Rajagopalan, K. Berrada, T. Yi, J.P. Kinet, and E.O. Long. 1996. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor.Immunity. 4:77-85.
Cashman, J.D., A.C. Eaves, E.W. Raines, R. Ross, and C.J. Eaves. 1990. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta.Blood. 75:96-101.
Cesano, A., G. Pierson, S. Visonneau, A.R. Migliaccio, and D. Santoli. 1996. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.Blood. 87:393-403.
Cesano, A., S. Visonneau, L. Cioe, S.C. Clark, G. Rovera, and D. Santoli. 1994. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.J Clin Invest. 94:1076-84.
Cesano, A., S. Visonneau, L. Cioe, S.C. Clark, and D. Santoli. 1995. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.Cancer Immunol Immunother. 40:139-51.
Cesano, A., S. Visonneau, K.A. Jeglum, J. Owen, K. Wilkinson, K. Carner, L. Reese, and D. Santoli. 1996b. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.Cancer Res. 56:3021-9.
Chang, H., J.A. Blondal, S. Benchimol, M.D. Minden, and H.A. Messner. 1995. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.Leuk Lymphoma. 19:165-71.
Chin, K.C., G. Li, and J.P. Ting. 1997. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants.J Immunol. 159:2789-94.
De Bruyn et al., “Coexpression of CD38, CD33 and HLA-DR Antigens on Human Cord Blood and Bone Marrow CD34 Cells,” Blood, 1994, p. 498a, Abstract 1976.
Ellis, T.M., and R.I. Fisher. 1989. Functional heterogeneity of Leu 19“bright”+and Leu 19“dim”+ lymphokine-activated killer cells.J Immunol. 142:2949-54.
Felgner, P.L., T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop, G.M. Ringold, and M. Danielsen. 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.Proc Natl Acad Sci U S A. 84:7413-7.
Fernandez, L.A., B. Pope, C. Lee, and E. Zayed. 1986. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.Blood. 67:925-30.
Gambacorti-Passerini, C., L. Rivoltini, M. Fizzotti, M. Rodolfo, M.L. Sensi, C. Castelli, A. Orazi, N. Polli, M. Bregni, S. Siena, and et al. 1991. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.Br J Haematol. 78:197-205.
Goldfarb, R.H., T.L. Whiteside, P.H. Basse, W.C. Lin, N. Vujanovic, and R.B. Herberman. 1994. Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases.Nat Immun. 13:131-40.
Gong, J.H., G. Maki, and H.G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.Leukemia. 8:652-8.
Goodman, D.J., M.A. von Albertini, A. McShea, C.J. Wrighton, and F.H. Bach. 1996. Adenoviral-mediated overexpression of I(kappa)B(alpha) in endothelial cells inhibits natural killer cell-mediated endothelial cell activation.Transplantation. 62:967-72.
Herberman, R.B., and J.R. Ortaldo. 1981. Natural killer cells: their roles in defenses against disease.Science. 214:24-30.
Kitamura, T., T. Tange, T. Terasawa, S. Chiba, T. Kuwaki, K. Miyagawa, Y.F. Piao, K. Miyazono, A. Urabe, and F. Takaku. 1989. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin.J Cell Physiol. 140:323-34.
Klingemann, H.G., H.J. Gong, G. Maki, D.E. Horsman, B.I. Dalal, and G.L. Phillips. 1994. Establishment and characterization of a human leukemic cell line (SR-91) with features suggestive of early hematopoietic progenitor cell origin.Leuk Lymphoma. 12:463-70.
Klingemann, et al., “A Cytotoxic NK-Cell Line (NK-92) for Ex Vivo Purging of Leukemia from Blood,” Biol. Blood Marrow Transplant, 1996, pp. 68-75, vol. 2).
Klingemann, H.G., and E. Wong. 1991. Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.Cancer Immunol Immunother. 33:395-7.
Komatsu, F., and M. Kajiwara. 1998. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface makers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.Oncol. Res. 10:483-9.
Komiyama, A., H. Kawai, Y. Miyagawa, and T: Akabane. 1982. Childhood lymphoblastic leukemia with natural killer activity: establishment of the leukemia cell lines retaining the activity.Blood. 60:1429-36.
Korbelik, M. and J. Sun. 2001. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line.Int. J. Cancer. 93, 269-274.
Lai, C.F., J. Ripperger, K.K. Morella, J. Jurlander, T.S. Hawley, W.E. Carson, T. Kordula, M.A. Caligiuri, R.G. Hawley, G.H. Fey, and H. Baumann. 1996. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements.J Biol Chem. 271:13968-75.
Lange, B., M. Valtieri, D. Santoli, D. Caracciolo, F. Mavilio, I. Gemperlein, C. Griffin, B. Emanuel, J. Finan, P. Nowell, and et al. 1987. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines.Blood. 70:192-9.
Lanier, L.L., A.M. Le, C.I. Civin, M.R. Loken, and J.H. Phillips. 1986. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.J Immunol. 136:4480-6.
Liu et al., “Addition of B Cell Depleti
Cohen & Grigsby P.C.
Conkwest, Inc.
Schwadron Ronald
LandOfFree
Interleukin-secreting natural killer cell lines and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-secreting natural killer cell lines and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-secreting natural killer cell lines and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289022